131 related articles for article (PubMed ID: 9873879)
1. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
Teitel JM; Card R; Strawczynski H
Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
[TBL] [Abstract][Full Text] [Related]
2. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.
Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA
Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733
[TBL] [Abstract][Full Text] [Related]
3. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
[TBL] [Abstract][Full Text] [Related]
4. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
Sabin C; Pasi J; Phillips A; Elford J; Janossy G; Lee C
Thromb Haemost; 1994 Aug; 72(2):214-7. PubMed ID: 7831654
[TBL] [Abstract][Full Text] [Related]
5. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
6. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
[TBL] [Abstract][Full Text] [Related]
7. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
Giles AR; Rivard GE; Teitel J; Walker I
Transfus Sci; 1998 Jun; 19(2):139-48. PubMed ID: 10187039
[TBL] [Abstract][Full Text] [Related]
8. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM
Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat-inactivated factor concentrates.
Shen MC; Hu FC; Lin JS; Tsai W; Fon MF; Wang EC
Haemophilia; 1998 Jan; 4(1):33-40. PubMed ID: 9873863
[TBL] [Abstract][Full Text] [Related]
10. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
Goldsmith JM; Deutsche J; Tang M; Green D
Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
[TBL] [Abstract][Full Text] [Related]
11. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate.
de Biasi R; Rocino A; Miraglia E; Mastrullo L; Quirino AA
Blood; 1991 Oct; 78(8):1919-22. PubMed ID: 1822966
[TBL] [Abstract][Full Text] [Related]
12. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate.
Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N
Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642
[TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
14. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
[TBL] [Abstract][Full Text] [Related]
15. Effect of intermediate- and high-purity factor VIII concentrates on immune function in HIV-seropositive haemophiliacs as assessed by quantitative CD 4 counts.
Deitcher SR; Tuller J; Dugdale M
Haemophilia; 1997 Oct; 3(4):265-9. PubMed ID: 27214862
[TBL] [Abstract][Full Text] [Related]
16. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D
Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234
[TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
18. [The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].
Montoro Ronsano JB; Oliveras Martín J; Tusell Puigbert JM
Med Clin (Barc); 1994 Nov; 103(18):690-4. PubMed ID: 7808075
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?
Eichinger S; Pabinger I; Kyrle PA; Köller U; Kier P; Schneider B; Lechner K
Haemostasis; 1992; 22(1):25-31. PubMed ID: 1521824
[TBL] [Abstract][Full Text] [Related]
20. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
